Results 11 to 20 of about 5,057,415 (322)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

open access: yesInternational Journal of Molecular Sciences, 2021
Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-α binds to two
Dan-in Jang   +7 more
semanticscholar   +1 more source

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

open access: yesScience, 2020
Targeting a key enzyme in SARS-CoV-2 Scientists across the world are working to understand severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Zhang et al.
Linlin Zhang   +8 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy

open access: yesCurrent Oncology, 2022
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy.
Y. Shiravand   +8 more
semanticscholar   +1 more source

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

open access: yesNew England Journal of Medicine, 2020
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain.
M. Vaduganathan   +5 more
semanticscholar   +1 more source

In situ click chemistry generation of cyclooxygenase-2 inhibitors

open access: yesNature Communications, 2017
Cyclooxygenase-2 isozyme is a promising anti-inflammatory drug target, and overexpression of this enzyme is also associated with several cancers and neurodegenerative diseases.
A. Bhardwaj, J. Kaur, M. Wuest, F. Wuest
semanticscholar   +1 more source

DNA sequencing with chain-terminating inhibitors.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1977
A new method for determining nucleotide sequences in DNA is described. It is similar to the "plus and minus" method [Sanger, F. & Coulson, A. R. (1975) J. Mol. Biol.
F. Sanger, S. Nicklen, A. Coulson
semanticscholar   +1 more source

CDK inhibitors: positive and negative regulators of G1-phase progression.

open access: yesGenes & Development, 1999
Mitogen-dependent progression through the first gap phase (G1) and initiation of DNA synthesis (S phase) during the mammalian cell division cycle are cooperatively regulated by several classes of cyclin-dependent kinases (CDKs) whose activities are in ...
C. Sherr, James M. Roberts
semanticscholar   +1 more source

Emerging therapeutic opportunities for integrin inhibitors

open access: yesNature reviews. Drug discovery, 2021
Integrins are cell adhesion and signalling proteins crucial to a wide range of biological functions. Effective marketed treatments have successfully targeted integrins αIIbβ3, α4β7/α4β1 and αLβ2 for cardiovascular diseases, inflammatory bowel disease ...
R. Slack   +4 more
semanticscholar   +1 more source

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

open access: yesScience Translational Medicine, 2011
Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors. The Shifting Sands of Lung Cancer Lung cancer is the leading cause of death globally and has proven very difficult to treat.
L. Sequist   +21 more
semanticscholar   +1 more source

Design and Optimization of Thioglycosyl–naphthalimides as Efficient Inhibitors Against Human O-GlcNAcase

open access: yesFrontiers in Chemistry, 2019
β-N-acetylhexosaminidases represent an important class of exoglycosidases and have emerged as the promising targets for drug and pesticide discovery. Among these, human O-GlcNAcase (hOGA) has been reported to be closely linked to several diseases such as
Shengqiang Shen   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy